162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use

About this episode

Amaal Starling discusses the INFUSE trial data and its implications for real-world treatment of migraines.

Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection. Looking for more Headache…

People in this episode

Host: Amaal Starling

Guest: Amaal Starling Md Fahs Faan

Topics covered

• INFUSE Trial
• eptinezumab
• migraine
• CGRP preventive options
• real world study
• clinical practice
• precision medicine

Keywords

• clinical perspective
• treatment sequencing
• patient experience
• predictive modeling

Mentioned in this episode

Products: eptinezumab

More episodes of NeurologyLive® Mind Moments®

• 168: Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine · June 12, 2026 · 18 min
• 167: New AASM Guidance on Combination Treatment for Chronic Insomnia · May 29, 2026 · 20 min
• 166: Understanding RNFL Asymmetry as a Biomarker in Pediatric MS · May 15, 2026 · 15 min
• 165: Addressing Cognitive Decline in Parkinson Disease · May 1, 2026 · 20 min
• 164: Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians · April 17, 2026 · 25 min
• 163: The Clinical Reality of Seronegative Myasthenia Gravis · April 3, 2026 · 17 min